Recursion Pharmaceuticals (RXRX) Short term Debt (2023 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Short term Debt came in at $9.3 million in Q1 2026, up 7.9% YoY from $8.6 million in Q1 2025, and up 1.91% on a QoQ basis from $9.1 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Short term Debt (2023 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 4 years of Short term Debt data on file, last reported at $9.3 million in Q1 2026.
- Quarterly Short term Debt rose 7.9% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 7.9% YoY) and the FY2025 annual result came in at $9.1 million, up 7.91% from the prior year.
- Short term Debt improved to $9.3 million in Q1 2026, from $9.1 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $9.3 million in Q1 2026 to a low of $41000.0 in Q4 2023.
- A 4-year average of $7.7 million and a median of $8.6 million in 2025 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2024 — Short term Debt surged 20448.78% — and 2026, when it rose 7.9%.
- Tracing RXRX's Short term Debt over 4 years: stood at $41000.0 in 2023, then surged by 20448.78% to $8.4 million in 2024, then advanced by 7.91% to $9.1 million in 2025, then advanced by 1.91% to $9.3 million in 2026.
- The last three Short term Debt figures came in at $9.3 million (Q1 2026), $9.1 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.44 Mn |
| Mar 31, 2026 | 9.27 Mn |
| Dec 31, 2025 | 9.09 Mn |
| Sep 30, 2025 | 8.92 Mn |
| Jun 30, 2025 | 8.75 Mn |
| Mar 31, 2025 | 8.59 Mn |
| Dec 31, 2024 | 8.43 Mn |
| Sep 30, 2024 | 8.22 Mn |
| Jun 30, 2024 | 8.11 Mn |
| Dec 31, 2023 | 41,000.00 |